Abstract
Only 20 % of patients have hyperuricemia implemented in gout as a clinically defined disease. In Madrid, at the Congress of the European League Against Rheumatism (EULAR) in 2013, it was concluded that gout is two different diseases, one of which is metabolic and manifests as hyperuricemia (also called “chemical gout”), and the other the gout component is actually a typical inflammation of the joints of the favorite localization due to the deposition of sodium monourate crystals in the tissues. That is, gout is always hyperuricemia, but hyperuricemia is not always gout.The main principles of gout management are the treatment of acute gout attack with colchicine, non-steroidal anti-inflammatory drugs, glucocorticosteroids, and combinations thereof; further prevention of acute attack with minimal doses of the aforementioned drugs; long-term lifesaving therapy. A non-purine selective xanthine oxidase inhibitor with potent hypouricemic action and evidence-based febuxostat is thought to be 2–3 times more effective than allopurinol.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
